The brain-computer interface market will not be a monopoly but a diverse ecosystem of many companies and products, analogous to the pharmaceutical industry [5].
A key motivation for developing advanced human-computer interfaces, as exemplified by Elon Musk's Neuralink, is to ensure humanity can merge with AI to avoid being dominated by superintelligence [16].
The future of neural interfaces may lie in 'bio-hybrid' devices that integrate living, engineered human neurons with electronic implants to create a more seamless and stable connection with the nervous system [21].
The flow of innovation has reversed, with artificial intelligence research now providing more insights to neuroscience than neuroscience provides to AI [13].
Significant business opportunities exist in improving the affordability and portability of existing, expensive medical support systems, such as ECMO and organ perfusion machines [15, 17].
A few years ago
Science acquired a small European company to obtain the core technology for its current retinal prosthesis, which was originally invented at Stanford University [20].
Previous Year
Science completed a large clinical trial for its retinal implant across 17 sites in Europe [22, 28].
Last Fall
The results of the retinal implant clinical trial were published in the New England Journal of Medicine. In the same period, Science also published a paper on its development of the world's most sensitive optogenetic proteins [22, 23].
Current Year
Science is submitting its retinal implant for market approval and expects to receive it later in the year [25].
Next 5-7 Years
Hodak estimates this is the timeframe for the clinical translation of Science's in-house optogenetic gene therapy [29].
Next 10 Years
Hodak predicts that retinal prosthetics will be able to achieve near-native acuity, comparable to 20/20 vision with color and a full field of view [1].
2035
Hodak identifies this year as his personal 'event horizon,' beyond which he feels the pace of technological change makes the future unpredictable [18].
▶The Commercialization of Advanced Vision Restoration
Hodak is intensely focused on bringing a retinal prosthesis to market to treat blindness from conditions like geographic atrophy. He details a clear business and clinical path, from acquiring the core technology and running a large European trial to publishing in a top journal and submitting for regulatory approval, while also developing next-generation optogenetic therapies [9, 20, 22, 23, 25].
Hodak's strategy of acquiring, iterating, and rapidly commercializing a proven technology de-risks the deep-tech venture, providing a potential revenue stream to fund more ambitious, long-term projects like bio-hybrid interfaces.
▶The Future Landscape of Brain-Computer Interfaces
Hodak envisions the BCI field not as a single-product market but as a diverse industry akin to pharmaceuticals, with many companies and applications. He discusses the philosophical motivations for BCI development, such as Elon Musk's goal of merging humanity with AI, and explores novel future technologies like bio-hybrid interfaces and ultrasound-based brain stimulation [5, 16, 21, 27].
This perspective suggests the BCI market will likely fragment into specialized verticals (e.g., motor restoration, sensory prosthetics, cognitive enhancement), creating opportunities for multiple successful companies rather than a single 'winner-take-all' platform.
▶Solving the Economic Bottlenecks of Advanced HealthcareApr 2026
Hodak repeatedly highlights the prohibitive costs of modern advanced medical care, from million-dollar gene therapies to half-million-dollar monthly ECMO bills and expensive organ transport systems. His company's 'Vessel' project, aimed at creating portable and affordable perfusion technology, is a direct attempt to solve these economic and logistical challenges [4, 8, 15, 17].
By targeting the high ancillary costs of advanced medicine, Hodak's company is building a business model around enabling technologies that could make currently unscalable treatments economically viable and widely accessible.
▶Technological Acceleration and Speculative FuturesApr 2026
Hodak operates with a strong sense of rapid technological progress, noting his personal predictive 'event horizon' is only the year 2035. He makes bold predictions about achieving near-native vision restoration within a decade and speculates on radical possibilities, such as 1,000-year lifespans for people alive today, driven by the accelerating interplay between fields like AI and neuroscience [1, 13, 18, 30].
Hodak's speculative but technologically-grounded futurism likely informs his company's high-risk, high-reward R&D strategy, justifying investment in moonshot projects that could redefine medicine and human potential.